Aptamer Group Signs £465,000 Agreement for Development of Cervical Cancer Blood Test

22 May 2024 | Wednesday | News

Optimer Binders to Revolutionize Early Detection and Replace Invasive Smear Tests in Partnership with Timser Group
Image Source : Public Domain

Image Source : Public Domain

  • Agreement for up to £465,000 signed for Optimer development
  • Optimer binders will be developed for use in a cervical cancer blood test

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

Under the terms of the agreement, Aptamer Group will develop Optimer binders to Timser’s patented cervical cancer biomarker panel – a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world’s first blood test for cervical cancer, preventing invasive smear tests and delivering earlier, more sensitive diagnostics.

Pairs of Optimer binders will be developed to each of the three biomarker proteins that form the unique cervical cancer signature. Timser will receive a licence for the use of the Optimers in its specific test combination, which is patented in 21 countries, including the USA.

Cervical cancer is the fourth most common cancer type in women worldwide. Present screening methods rely on invasive and relatively low sensitivity Papanicolaou (PAP) smear tests. The Optimer enabled Timser’s diagnostic will allow earlier detection at the precancerous lesion stage, which is associated with increased survival. Use of a blood-based test over traditional PAP smears will offer the potential for increased detection rates by improving uptake due to the less invasive testing method.

As Timser expands its diagnostic tests into diverse markets, including low-income countries, the Optimer binders offer advantages to support continued supply and quality. With superior shelf-life and enhanced temperature stability compared to antibodies, Optimer binders facilitate global test distribution without compromising quality or performance. Previous attempts by Timser to develop antibodies to support the test have failed due to issues with antibody batch variability and supply chains. Unlike antibodies, Optimer binders are chemically manufactured, giving consistent quality, with the potential to use multiple manufacturers both locally and globally to prevent supply chain issues.

“We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests.” Dr Arron Tolley, Chief Technical Officer of Aptamer Group


“We are equally excited about this collaboration with Aptamer Group. The potential of Optimer binders to enhance the accuracy and reliability of our cancer diagnostics tests is truly promising. By integrating this advanced technology, we are confident in our ability to overcome the limitations of traditional antibodies and improve the outcomes for patients undergoing cervical cancer screening. We look forward to a successful partnership and to witnessing the impact that this new technology will have for women across the globe.” Mercedes Gutierrez, Chief Executive Officer of TIMSER Group


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in